Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 19/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.80 |
| ▸ | SLC2A9 | Q9NRM0 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19867808 | 0.90 | SLC22A12 (0.76) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Lesinurad SCHEMBL29353441 | 0.89 | SLC22A12 (1.00) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Lesinurad SCHEMBL842962 | 0.89 | SLC22A12 (1.00) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Lesinurad SCHEMBL2265513 | 0.88 | SLC22A12 (0.98) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL12379317 | 0.88 | SLC22A12 (0.71) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL16500465 | 0.86 | SLC22A12 (0.82) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL1299832 | 0.86 | SLC22A12 (0.82) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4735350 | 0.86 | SLC22A12 (0.82) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL21160793 | 0.86 | SLC22A12 (0.75) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Lesinurad SCHEMBL1299308 | 0.85 | SLC22A12 (0.81) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-8546437-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8524754-B2 | Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio) acetate, and uses thereof | ARDEA BIOSCIENCES, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8357713-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-8283369-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES. INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120164222-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120129903-A1 | POLYMORPHIC, CRYSTALLINE AND MESOPHASE FORMS OF SODIUM 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO) ACETATE, AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8084483-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-8003681-B2 | 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester | ARDEA BIOSCIENCES, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100081827-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | ARDEA BIOSCIENCES, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100069645-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | ARDEA BIOSCIENCES, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069645-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | GRHPR, POLR2H, ME2 | SLC22A12 1037/4885CYP2C9 927/4885CYP2C19 1109/4885 |
| US-20120164222-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | SPR, POLR2H, QTRT1 | SLC22A12 1536/4885CYP2C9 381/4885CYP2C19 660/4885 |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-20100081827-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | GRHPR, POLR2H, DECR1 | SLC22A12 1207/4885CYP2C9 840/4885CYP2C19 1020/4885 |
| US-20120129903-A1 | POLYMORPHIC, CRYSTALLINE AND MESOPHASE FORMS OF SODIUM 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO) ACETATE, AND USES THEREOF | SLC10A1, SLC5A1, HSD3B1 | SLC22A12 200/4885CYP2C9 376/4885CYP2C19 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.